“fda” Archives

in
Entry Author Date Location
Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4 10/15/20 National
Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects 10/15/20 Boston
Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma 10/13/20 San Diego
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D 10/12/20 Boston
“Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug 10/12/20 New York
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats 10/09/20 Europe
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility 10/08/20 Boston
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug 10/08/20 National
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter 10/06/20 San Francisco
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More 10/02/20 National
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume 10/01/20 Boston
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries 10/01/20 Europe
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug 09/30/20 New York
Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins 09/29/20 Europe
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs 09/28/20 Boston
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs 09/24/20 Boston
Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function” 09/23/20 Seattle
Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations 09/22/20 National
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D 09/17/20 Boston
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline 09/17/20 Boston
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug 09/16/20 Wisconsin
Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy 09/15/20 Europe
Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug 09/15/20 San Francisco
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals 09/14/20 Seattle
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout 09/14/20 San Francisco
Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test 09/10/20 San Francisco
Q&A: BIO CEO Michelle McMurray-Heath Outlines Diversity Goals 09/05/20 National
AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase 09/04/20 National
Page 1 of 89 next page »